行情

VSTM

VSTM

Verastem
NASDAQ

实时行情|Nasdaq Last Sale

2.995
+0.075
+2.57%
交易中 15:54 04/08 EDT
开盘
2.940
昨收
2.920
最高
3.140
最低
2.900
成交量
283.29万
成交额
--
52周最高
3.490
52周最低
0.8300
市值
4.44亿
市盈率(TTM)
-1.4968
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测VSTM价格均价为4.083,最高价位6.00,最低价为2.750。

EPS

VSTM 新闻

更多
  • Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • Business Wire · 22小时前
  • Earnings Estimates Moving Higher for Verastem (VSTM): Time to Buy?
  • Zacks · 03/30 14:37
  • Verastem Oncology: An Undervalued KRAS Oncology Play
  • Seeking Alpha - Article · 03/30 07:45
  • Top Drug Stocks Under $5
  • MotleyFool.com · 03/26 11:36

所属板块

生物技术和医学研究
+3.33%
制药与医学研究
+3.44%

热门股票

代码
价格
涨跌幅

VSTM 简况

Verastem, Inc., is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. It is also developing a dual inhibitor of PI3K-delta and PI3K-gamma, which has completed Phase 2 study in indolent non-hodgkin lymphoma. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma.
展开

微牛提供Verastem Inc(NASDAQ-VSTM)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的VSTM股票新闻,以帮助您做出投资决策。